Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL887105 | 0.94 | LMNA (0.59) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Gluconic Acid SCHEMBL3389955 | 0.91 | LMNA (0.59) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL10596732 | 0.84 | PDE4A (0.47) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Gluconic Acid SCHEMBL3710793 | 0.81 | LMNA (0.65) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Mannitol SCHEMBL4182132 | 0.81 | LMNA (0.61) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Silver SCHEMBL18889837 | 0.81 | LMNA (0.58) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Gluconic Acid SCHEMBL547729 | 0.80 | LMNA (0.62) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL9360101 | 0.79 | LMNA (0.56) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL9142871 | 0.79 | PDE4A (0.59) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Potassium Ion SCHEMBL3187155 | 0.79 | LMNA (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434869-B1 | METHOD FOR PREPARING CALCIUM GLUCONATE | PURAC BIOCHEM NV (NL) | 2010-12-15 | — | — | EP | claimed |
| US-20090104339-A1 | METHOD FOR PREPARING CALCIUM GLUCONATE | PURAC BIOCHEM B.V. (NL) | 2009-04-23 | — | — | US | claimed |
| US-20040253345-A1 | Method for preparing calcium gluconate | PURAC BIOCHEM B.V. (NL) | 2004-12-16 | — | — | US | claimed |
| EP-1434869-B1 | METHOD FOR PREPARING CALCIUM GLUCONATE | PURAC BIOCHEM NV (NL) | 2010-12-15 | — | — | EP | disclosed |
| US-7618664-B2 | Method for preparing calcium gluconate | COOPERATIEVE VERKOOP-EN PRODUCTIEVERENIGING VAN AARDAPPELMEEL EN DERIVATEN AVEBE B.A. (NL) | 2009-11-17 | — | — | US | disclosed |
| US-20090104339-A1 | METHOD FOR PREPARING CALCIUM GLUCONATE | PURAC BIOCHEM B.V. (NL) | 2009-04-23 | — | — | US | disclosed |
| US-20070003672-A1 | Tri-part calcium fortified compositions and methods of making the same | COCO-COLA COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070003671-A1 | Two-part calcium fortified compositions and methods of making the same | COCO-COLA COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20060270650-A1 | Combination therapy for the treatment of obesity | MACNEIL TANYA | 2006-11-30 | — | — | US | disclosed |
| US-20040253345-A1 | Method for preparing calcium gluconate | PURAC BIOCHEM B.V. (NL) | 2004-12-16 | — | — | US | disclosed |
| EP-1434869-A1 | METHOD FOR PREPARING CALCIUM GLUCONATE | PURAC BIOCHEM N.V. (NL) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003031635-A1 | METHOD FOR PREPARING CALCIUM GLUCONATE | PURAC BIOCHEM B.V. (NL) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270650-A1 | Combination therapy for the treatment of obesity | GPR119, GANC, GANAB | LMNA 1227/4885L3MBTL1 4698/4885PDE4A 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.